Abstract
By-products of complement activation and complement regulatory proteins are increasingly recognized to play an important pathogenic role in a variety of vascular diseases including atherosclerosis, ischemia and reperfusion injury, hyperacute graft rejection, vasculitis, and the vascular complications of human diabetes. “Self” damage by autologous complement is mediated by activation products of the complement cascades or by direct insertion of the membrane attack complex (MAC) into cell membranes. Specifically, insertion of MAC complexes into endothelial cells results in the release of an array of growth factors and cytokines that induces proliferation, inflammation and thrombosis in the vascular wall. This paper reviews complement and complement regulatory proteins with specific focus on the vasculature and vascular diseases; it highlights complement and its regulators as potential targets for the rational design of mechanismspecific drugs for the treatment of some of the most prevalent human diseases.
Keywords: Proteins, mechanismspecific, vasculitis, thrombosis, MAC complexes
Current Pharmaceutical Design
Title: Complement and Complement Regulatory Proteins as Potential Molecular Targets for Vascular Diseases
Volume: 10 Issue: 2
Author(s): Juan Acosta, Xuebin Qin and Jose Halperin
Affiliation:
Keywords: Proteins, mechanismspecific, vasculitis, thrombosis, MAC complexes
Abstract: By-products of complement activation and complement regulatory proteins are increasingly recognized to play an important pathogenic role in a variety of vascular diseases including atherosclerosis, ischemia and reperfusion injury, hyperacute graft rejection, vasculitis, and the vascular complications of human diabetes. “Self” damage by autologous complement is mediated by activation products of the complement cascades or by direct insertion of the membrane attack complex (MAC) into cell membranes. Specifically, insertion of MAC complexes into endothelial cells results in the release of an array of growth factors and cytokines that induces proliferation, inflammation and thrombosis in the vascular wall. This paper reviews complement and complement regulatory proteins with specific focus on the vasculature and vascular diseases; it highlights complement and its regulators as potential targets for the rational design of mechanismspecific drugs for the treatment of some of the most prevalent human diseases.
Export Options
About this article
Cite this article as:
Acosta Juan, Qin Xuebin and Halperin Jose, Complement and Complement Regulatory Proteins as Potential Molecular Targets for Vascular Diseases, Current Pharmaceutical Design 2004; 10 (2) . https://dx.doi.org/10.2174/1381612043453441
DOI https://dx.doi.org/10.2174/1381612043453441 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pathogenesis and Therapeutics of Interstitial Lung Disease in Systemic Sclerosis
Current Rheumatology Reviews Pharmacogenetically Tailored Treatments for Heart Disease
Current Pharmaceutical Design Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update
Current Neuropharmacology Clinical Applications of Autoimmunity to Citrullinated Proteins in Rheumatoid Arthritis, from Improving Diagnostics to Future Therapies
Recent Patents on Inflammation & Allergy Drug Discovery Monoclonal Antibodies in the Treatment of Systemic Lupus Erythematosus
Current Drug Targets Uveitis in Rheumatic Diseases
Current Rheumatology Reviews Viral Encephalitis: Current Treatments and Future Perspectives
Central Nervous System Agents in Medicinal Chemistry Anti-VEGF Treatment in Corneal Diseases
Current Drug Targets Editorial [Hot Topic: Applications of Angiotensin Converting Enzyme Inhibitors and of Angiotensin II Receptor Blockers in Pharmacology and Therapy: An Update (Executive Editor: Agostino Molteni)]
Current Pharmaceutical Design Treatment of Central Nervous System Tuberculosis Infections and Neurological Complications of Tuberculosis Treatment
Current Pharmaceutical Design Angiogenesis as Risk Factor for Plaque Vulnerability
Current Pharmaceutical Design Epigenetic control of cardiovascular health by nutritional polyphenols involves multiple chromatin-modifying writer-reader-eraser proteins
Current Topics in Medicinal Chemistry Applications of FDG-PET/CT in Assessment of Vascular Infection and Inflammation
Current Molecular Imaging (Discontinued) Prevalence of Anti-nuclear and Anti-phospholipid Antibodies in an Egyptian Cohort with Schizophrenia: A Case-control Study
Current Rheumatology Reviews Mesenchymal Stem Cells: Key Actors in Tumor Niche
Current Stem Cell Research & Therapy Strategies for Leukotriene Modulation in Dermatology: Current Evidence and Visionary Perspectives
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Anti-Inflammatory and Anti-Neoplastic Actions of Resveratrol
Current Nutrition & Food Science The Role of COX-2 in Heart Pathology
Cardiovascular & Hematological Agents in Medicinal Chemistry Phytochemicals in the Treatment of Alzheimer’s Disease: A Systematic Review
Current Drug Targets The Lung in Immune-Mediated Disorder: Rheumatoid Arthritis
Current Drug Targets - Inflammation & Allergy